Table 2: Comparison of outcomes measurements among the 3 groups.

VariableGroupWeek 0Week 1Week 2Week 3 Followup

FMAFour-channel14.5 ± 5.118.7 ± 4.9##20.6 ± 5.1##21.8 ± 4.9##23.3 ± 4.9
Placebo14.8 ± 5.616.6 ± 6.2##17.9 ± 5.5##18.2 ± 5.4##19.5 ± 6.2
Dual-channel 14.3 ± 5.115.9 ± 5.1#16.8 ± 5.5##17.3 ± 5.6 19.3 ± 6.4

PASSFour-channel18.9 ± 8.826.6 ± 5.5##28.9 ± 4.8##29.8 ± 4.3##30.9 ± 3.4
Placebo20.4 ± 9.122.1 ± 8.9##23.8 ± 8.2##24.1 ± 8.1 25.7 ± 8.2
Dual-channel 19.6 ± 10.122.0 ± 9.1##24.5 ± 8.4##25.4 ± 8.6#26.8 ± 8.5

BBSFour-channel17.2 ± 14.930.4 ± 14.9#37.6 ± 14.0#39.1 ± 13.5#42.7 ± 11.2
Placebo16.5 ± 16.721.1 ± 18.0#24.4 ± 18.1 25.4 ± 18.3 29.3 ± 18.7*
Dual-channel 16.3 ± 16.319.5 ± 16.8#24.8 ± 15.6 27.4 ± 16.1#31.9 ± 18.6

MBIFour-channel48.9 ± 23.865.7 ± 20.3#76.3 ± 15.6#80.3 ± 16.5#87.4 ± 15.2
Placebo48.5 ± 21.758.0 ± 22.3#64.3 ± 19.9#66.7 ± 19.1 72.9 ± 21.9*
Dual-channel 48.1 ± 22.655.3 ± 21.8#62.5 ± 19.5 64.6 ± 17.8 75.8 ± 21.8

FACFour-channel1.1 ± 1.41.5 ± 1.42.4 ± 1.52.6 ± 1.63.5 ± 1.5
Placebo0.8 ± 1.31.0 ± 1.41.5 ± 1.41.5 ± 1.32.3 ± 1.9
Dual-channel 0.7 ± 1.10.8 ± 1.11.1 ± 1.11.4 ± 1.12.4 ± 1.8

Value: mean ± SD. , indicate significant differences when comparing the score of all outcomes for week 1 to followup at 3 months after the 3-week treatment ended with week 0 within-group. indicates significant difference when compared with the four-channel group.